Autolus Therapeutics plc Professional Fees
Autolus Therapeutics plc (AUTL) reported Professional Fees of $1.60 million for the 12-month period ending 2022-12-31, per its 20-F filed 2023-03-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ProfessionalFees · last filed 2023-03-07
- Autolus Therapeutics plc professional fees for the quarter ending 2021-03-31 was $500.00K, a 16.67% decline year-over-year.
- Autolus Therapeutics plc professional fees for the quarter ending 2020-12-31 was $500.00K, a 16.67% decline year-over-year.
- Autolus Therapeutics plc professional fees for the quarter ending 2020-09-30 was $400.00K, a 20.00% decline year-over-year.
- Autolus Therapeutics plc professional fees for the quarter ending 2020-06-30 was $600.00K, a 20.00% increase year-over-year.
| Period end | Professional Fees 3 month | Professional Fees 6 month | Professional Fees 9 month | Professional Fees 12 month |
|---|---|---|---|---|
| 2022-12-31 | $1.60M 20-F · filed 2023-03-07 | |||
| 2021-12-31 | $1.70M 20-F · filed 2023-03-07 | |||
| 2021-03-31 | $500.00K 6-K · filed 2021-05-06 | $1.00M derived: sum of 2 quarters · filed 2023-03-07 | $1.40M derived: sum of 3 quarters · filed 2023-03-07 | $2.00M derived: sum of 4 quarters · filed 2023-03-07 |
| 2020-12-31 | $500.00K derived: 20-F 12 month − 6-K 9 month · filed 2023-03-07 | $900.00K derived: sum of 2 quarters · filed 2023-03-07 | $1.50M derived: sum of 3 quarters · filed 2023-03-07 | $2.10M 20-F · filed 2023-03-07 |
| 2020-09-30 | $400.00K 6-K · filed 2020-11-05 | $1.00M derived: sum of 2 quarters · filed 2020-11-05 | $1.60M 6-K · filed 2020-11-05 | $2.20M derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-06-30 | $600.00K 6-K · filed 2020-08-06 | $1.20M 6-K · filed 2020-08-06 | $1.80M derived: sum of 3 quarters · filed 2022-03-10 | $2.30M derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-03-31 | $600.00K 6-K · filed 2021-05-06 | $1.20M derived: sum of 2 quarters · filed 2022-03-10 | $1.70M derived: sum of 3 quarters · filed 2022-03-10 | $2.20M derived: sum of 4 quarters · filed 2022-03-10 |
| 2019-12-31 | $600.00K derived: 20-F 12 month − 6-K 9 month · filed 2022-03-10 | $1.10M derived: sum of 2 quarters · filed 2022-03-10 | $1.60M derived: sum of 3 quarters · filed 2022-03-10 | $2.00M 20-F · filed 2022-03-10 |
| 2019-09-30 | $500.00K 6-K · filed 2020-11-05 | $1.00M derived: sum of 2 quarters · filed 2020-11-05 | $1.40M 6-K · filed 2020-11-05 | $1.50M derived: sum of 4 quarters · filed 2021-03-04 |
| 2019-06-30 | $500.00K 6-K · filed 2020-08-06 | $800.00K 6-K · filed 2020-08-06 | $1.00M derived: sum of 3 quarters · filed 2021-03-04 | $1.30M derived: sum of 4 quarters · filed 2021-03-04 |
| 2019-03-31 | $300.00K 6-K · filed 2020-05-07 | $500.00K derived: sum of 2 quarters · filed 2021-03-04 | $800.00K derived: sum of 3 quarters · filed 2021-03-04 | $1.60M derived: sum of 4 quarters · filed 2021-03-04 |
| 2018-12-31 | $200.00K 20-F · filed 2021-03-04 | $500.00K derived: sum of 2 quarters · filed 2021-03-04 | $1.30M derived: sum of 3 quarters · filed 2021-03-04 | |
| 2018-09-30 | $300.00K 6-K · filed 2019-11-07 | $1.10M derived: sum of 2 quarters · filed 2019-11-07 | $1.00M 20-F · filed 2021-03-04 | $1.00M 20-F · filed 2020-03-03 |
| 2018-06-30 | $800.00K 6-K · filed 2019-08-08 | $800.00K 6-K · filed 2019-08-08 | ||
| 2017-09-30 | $500.00K 20-F · filed 2020-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 |